Quest Diagnostics Incorporated
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Quest Diagnostics Incorporated
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.
- Diagnostic Imaging Services
- Other Names / Subsidiaries
- ADI Holding Company
- Athena Diagnostics
- Blueprint Genetics
- Boyce and Bynum Pathology Laboratories
- California Laboratory Associates (CLA)
- Celera Group
- Cleveland HeartLab Inc.
- Hurley Medical Center
- Pathway Diagnostics
- Shiel Medical Laboratory
- Solstas Lab Partners
- Summit Health
- Superior Mobile Medics
- Mid America Clinical Laboratories (MACL)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.